NautaDutilh assisted Merus N.V., an oncology company, in raising approximately USD 300 million in gross proceeds through an underwritten public offering of 5,263,158 common shares at a public offering price of USD 57.00 per share. Merus also granted the underwriters an option to purchase up to an additional 789,473 common shares. All of the shares in the offering are to be sold by Merus.
“We are honoured to have assisted Merus yet again on an important transaction in their journey to develop innovative antibody therapeutics. Merus is an inspiring company and a great team to work with.”
Next to Paul, our team consisted of Nina Kielman, Joppe Schoute, Elodie Smits, Eline van Marle and Marije Bader. The team worked alongside the US team of Latham & Watkins.
Press:
FD: Biotechbedrijf Merus uit Utrecht haalt $300 mln op met emissie
Merus: Merus N.V. Announces Pricing of Public Offering of Common Shares - Merus
